Viral Hepatitis
Copyright ©2007 Baishideng Publishing Group Inc.
World J Gastroenterol. Oct 21, 2007; 13(39): 5188-5195
Published online Oct 21, 2007. doi: 10.3748/wjg.v13.i39.5188
Figure 1
Figure 1 Schematic flow chart of enrolled patients.
Figure 2
Figure 2 A: Clinical course of the interferon group. Patients who had a curative treatment for primary HCC received 3 MIU of natural interferon-alpha three times weekly for at least 48 wk as long as possible except Cases 12, 14 and 16. Recurrent HCCs were treated with or without curative treatment; B: Clinical course of the non-interferon group. Patients who had a curative treatment of primary HCC did not receive IFN therapy. Recurrent HCCs were also treated with or without curative treatment.
Figure 3
Figure 3 A: Cumulative rate of first recurrence. Rates of first recurrence for the IFN and non-IFN groups. The rate of first recurrence of HCC in the IFN group was not significantly different from that of the non-IFN group (P = 0.157); B: Cumulative rate of second recurrence. Rates of second recurrence for the IFN and non-IFN group. The rate of second recurrence of HCC in the IFN group was not significantly different from that of the non-IFN group (P = 0.056).
Figure 4
Figure 4 Effect of IFN therapy after curative treatment of HCC on Child-Pugh scores. IFN-treated patients were less likely to show deterioration of hepatic function. The average scores of Child-Pugh of the IFN group were significantly better preserved than the non-IFN group (P = 0.0008).
Figure 5
Figure 5 Cumulative rate of deviation from objects of any treatment of recurrent HCC. Recurrent HCC tended to be treatable later in the IFN group than non-IFN group (P = 0.048).
Figure 6
Figure 6 Cumulative survival rate. Comparison of the cumulative survival rates of the IFN and non-IFN groups. The cumulative survival rate was not significantly different between the two groups (P = 0.45).